{"id":29506,"date":"2018-08-01T01:00:00","date_gmt":"2018-08-09T04:02:03","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/08\/09\/%e7%9b%98%e7%82%b9-%e4%b8%80%e6%96%87%e7%9c%8b%e6%87%82%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e7%96%97%e6%b3%95%e5%85%ad%e5%a4%a7%e6%9c%80%e6%96%b0%e8%bf%9b%e5%b1%95\/"},"modified":"2018-08-09T12:02:05","modified_gmt":"2018-08-09T04:02:05","slug":"%e7%9b%98%e7%82%b9-%e4%b8%80%e6%96%87%e7%9c%8b%e6%87%82%e8%82%bf%e7%98%a4%e5%85%8d%e7%96%ab%e7%96%97%e6%b3%95%e5%85%ad%e5%a4%a7%e6%9c%80%e6%96%b0%e8%bf%9b%e5%b1%95","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/29506\/","title":{"rendered":"\u76d8\u70b9 | \u4e00\u6587\u770b\u61c2\u80bf\u7624\u514d\u75ab\u7597\u6cd5\u516d\u5927\u6700\u65b0\u8fdb\u5c55"},"content":{"rendered":"
\n

\u258e\u836f\u660e<\/span><\/strong>\u5eb7\u5fb7\/\u62a5\u9053<\/span><\/strong><\/strong><\/span><\/strong><\/strong><\/span><\/strong><\/strong><\/strong><\/span><\/strong><\/strong><\/span><\/strong><\/strong><\/p>\n


<\/span><\/strong><\/strong><\/span><\/strong><\/strong><\/span><\/strong><\/strong><\/strong><\/span><\/strong><\/strong><\/span><\/strong><\/strong><\/p>\n

\n

\u56fe\u7247\u6765\u6e90\uff1a123RF<\/span><\/p>\n


<\/span><\/p>\n

1. \u9ed8\u6c99\u4e1cPD-1\u5355\u6297Keytruda\u5728\u4e2d\u56fd\u83b7\u6279\u4e0a\u5e02<\/span><\/strong><\/span><\/p>\n


<\/p>\n

7\u670826\u65e5\uff0c\u9ed8\u6c99\u4e1c\u5ba3\u5e03\uff0c\u5176PD-1\u6291\u5236\u5242\u836f\u7269\u5e15\u535a\u5229\u73e0\u5355\u6297\uff08Pembrolizumab\uff09\u6b63\u5f0f\u83b7\u5f97\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40<\/span>\u6279\u51c6<\/span><\/a>\uff0c\u7528\u4e8e\u7ecf\u4e00\u7ebf\u6cbb\u7597\u5931\u8d25\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u7684\u6cbb\u7597\u3002<\/span>\u622a\u81f3\u76ee\u524d\uff0c\u5e15\u535a\u5229\u73e0\u5355\u6297\u662f\u56fd\u5185\u552f\u4e00\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u665a\u671f\u9ed1\u8272\u7d20\u7624\u7684PD-1\u6291\u5236\u5242\u836f\u7269\uff0c\u6807\u5fd7\u7740\u4e2d\u56fd\u9ed1\u8272\u7d20\u7624\u6cbb\u7597\u81ea\u6b64\u8fc8\u5165\u514d\u75ab\u6cbb\u7597\u65f6\u4ee3\u3002\u4e2d\u56fd\u836f\u76d1\u7ba1\u7406\u90e8\u95e8\u7ed9\u4e88\u8fd9\u4e00\u80fd\u591f\u6ee1\u8db3\u4e2d\u56fd\u91cd\u5927\u533b\u7597\u9700\u6c42\u7684\u521b\u65b0\u6cbb\u7597\u836f\u7269\u4f18\u5148\u5ba1\u8bc4\u7684\u8d44\u683c\uff0c\u52a0\u901f\u5ba1\u6279\u901f\u5ea6\uff0c\u4ece\u63d0\u4ea4\u7533\u8bf7\u5230\u83b7\u6279\u4ec5\u7528\u77ed\u77ed\u4e94\u4e2a\u591a\u6708\u3002<\/span><\/p>\n


<\/p>\n

2. \u663e\u8457\u5ef6\u957f\u5934\u9888\u764cOS\uff0c\u9ed8\u6c99\u4e1cPD-1\u5355\u62973\u671f\u4e34\u5e8a\u6570\u636e\u51fa\u8272<\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u9ed8\u6c99\u4e1c\u5ba3\u5e03\uff0c\u5176\u91cd\u78c5\u514d\u75ab\u7597\u6cd5Keytruda\uff08pembrolizumab\uff09\u5728<\/span>\u4e00\u98793\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d<\/span><\/a>\uff0c\u4f5c\u4e3a\u590d\u53d1\u6216\u8f6c\u79fb\u6027\u5934\u9888\u9cde\u72b6\u7ec6\u80de\u764c\u7684\u4e00\u7ebf\u7597\u6cd5\uff0c\u663e\u8457\u5ef6\u957f\u4e86\u60a3\u8005\u7684\u603b\u751f\u5b58\u671f\uff0c\u8fbe\u5230\u4e86\u4e3b\u8981\u4e34\u5e8a\u7ec8\u70b9\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u8fd9\u4e5f\u662f\u9996\u6b3e\u5728\u4e00\u7ebf\u6cbb\u7597\u8be5\u75be\u75c5\u4e2d\uff0c\u5f70\u663e\u51fa\u4f18\u5f02\u603b\u751f\u5b58\u671f\u7684\u6297PD-1\u7597\u6cd5\u3002<\/span>KEYNOTE-048\u7814\u7a76\u62db\u52df\u4e86825\u540d\u60a3\u8005\uff0c\u4ed6\u4eec\u88ab\u968f\u673a\u5206\u4e3a\u591a\u7ec4\uff0c\u4e00\u7ec4\u63a5\u53d7Keytruda\u7684\u5355\u836f\u6cbb\u7597\uff0c\u4e00\u7ec4\u63a5\u53d7Keytruda\u4e0e\u5316\u7597\uff0c\u53e6\u4e00\u7ec4\u5219\u63a5\u53d7cetuximab\u4e0e\u5316\u7597\u3002\u5728\u4e00\u4e2a\u72ec\u7acb\u6570\u636e\u76d1\u5bdf\u59d4\u5458\u4f1a\u7684\u4e2d\u671f\u5206\u6790\u4e0b\uff0cKeytruda\u7684\u5355\u836f\u7597\u6cd5\u4e0e\u6807\u51c6\u7597\u6cd5\u76f8\u6bd4\uff0c\u5728\u60a3\u8005\u4e2d\u5e26\u6765\u4e86\u663e\u8457\u66f4\u957f\u7684\u603b\u751f\u5b58\u671f\u3002\u800c\u5176\u5b89\u5168\u6027\u5219\u4e0e\u4e4b\u524d\u7814\u7a76\u7684\u6570\u636e\u4fdd\u6301\u4e00\u81f4\u3002\u8be5\u7814\u7a76\u7684\u5177\u4f53\u7ed3\u679c\u5c06\u5728\u8fd1\u671f\u7684\u533b\u5b66\u4f1a\u8bae\u4e0a\u5f97\u5230\u516c\u5e03\u3002<\/span><\/p>\n


<\/p>\n

3. \u767e\u6d4e\u795e\u5ddePD-1\u5355\u6297\u8054\u5408\u5316\u7597\u4e00\u7ebf\u6cbb\u7597\u80ba\u764c\u5b8c\u6210\u9996\u4f8b\u60a3\u8005\u7ed9\u836f<\/span><\/strong><\/span><\/p>\n


<\/p>\n

7\u670824\u65e5\uff0c\u767e\u6d4e\u795e\u5dde\u516c\u53f8\u5ba3\u5e03\uff0c\u5176\u5728\u7814\u7684\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u836f\u7269PD-1\u6297\u4f53tislelizumab\u8054\u5408\u5316\u7597\u4f5c\u4e3a\u6f5c\u5728\u4e00\u7ebf\u7597\u6cd5\uff0c\u6cbb\u7597\u4e2d\u56fdIIIb\u671f\u6216IV\u671f\u975e\u9cde\u72b6\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u60a3\u8005\u7684\u4e34\u5e8a3\u671f\u8bd5\u9a8c\u5b9e\u73b0\u9996\u4f8b\u60a3\u8005\u7ed9\u836f\u3002<\/span>\u8be53\u671f\u4e34\u5e8a\u4e3b\u8981\u7528\u4ee5\u8bc4\u4f30\u5728\u76ee\u524d\u9488\u5bf9\u665a\u671f\u975e\u9cde\u72b6NSCLC\u60a3\u8005\u7684\u5168\u7403\u6807\u51c6\u6cbb\u7597\u65b9\u6848\u201c\u94c2\u52a0\u57f9\u7f8e\u66f2\u585e\u5316\u7597\u201d\u4e2d\u52a0\u5165\u5728\u7814\u514d\u75ab\u80bf\u7624\u836f\u7269tislelizumab\u7684\u6f5c\u5728\u5f71\u54cd\u3002<\/span><\/p>\n

\u672c\u6587\u6765\u6e90\uff1a\u836f\u660e\u5eb7\u5fb7<\/span><\/p>\n

Tislelizumab (BGB-A317)\u662f\u767e\u6d4e\u795e\u5dde\u5f00\u53d1\u7684\u4e00\u79cd\u5728\u7814\u4eba\u6e90\u6027\u5355\u514b\u9686\u6297\u4f53\uff0c\u5b83\u5c5e\u4e8e\u4e00\u7c7b\u88ab\u79f0\u4e3a\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7684\u80bf\u7624\u514d\u75ab\u836f\u7269\u3002<\/span>\u636e\u4ecb\u7ecd\uff0c\u8fd9\u98793\u671f\u3001\u5f00\u653e\u3001\u591a\u4e2d\u5fc3\u4e34\u5e8a\u8bd5\u9a8c\u9884\u8ba1\u5728\u4e2d\u56fd\u5927\u9646\u62db\u52df\u7ea6320\u4f4dIIIb\u671f\u6216IV\u671f\u672a\u7ecf\u5316\u7597\u6cbb\u7597\u7684\u975e\u9cde\u72b6NSCLC\u60a3\u8005\u3002\u8be5\u8bd5\u9a8c\u65e8\u5728\u5bf9\u6bd4\u7531\u72ec\u7acb\u8bc4\u5ba1\u59d4\u5458\u4f1a\uff08IRC\uff09\u8bc4\u4f30\u7684\u6839\u636eRECIST v1.1\u5b9a\u4e49\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u3002\u5173\u952e\u6b21\u8981\u7ec8\u70b9\u5305\u62ec\u603b\u751f\u5b58\u671f\u3001\u603b\u4f53\u7f13\u89e3\u7387\u3001\u7814\u7a76\u8005\u8bc4\u4f30\u7684PFS\u3001\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\u3002<\/span><\/p>\n


<\/p>\n

4. CBT\u5f00\u5c55PD-1\u6297\u4f53CBT-501-01\uff08genolimzumab\uff09\u76841b\u671f\u4e34\u5e8a\u8bd5\u9a8c<\/span><\/strong><\/span><\/p>\n


<\/p>\n

CBT Pharmaceuticals\uff08CBT\uff09\u662f\u4e00\u5bb6\u7f8e\u4e2d\u4e24\u5730\u7684\u521b\u65b0\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u5f00\u53d1\u80bf\u7624\u5b66\u8054\u5408\u7597\u6cd5\u3002\u8fd1\u65e5\uff0c\u8be5\u516c\u53f8\u5ba3\u5e03\u7ee7\u7eedCBT-501\uff08genolimzumab\u6ce8\u5c04\uff091\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5728\u7279\u5b9a\u7c7b\u578b\u7684\u665a\u671f\u6216\u590d\u53d1\u5b9e\u4f53\u7624\u60a3\u8005\u4e2d\u8fdb\u884c1b\u671f\u7814\u7a76\u3002CBT-501\u662f\u9488\u5bf9\u514d\u75ab\u7ec6\u80de\u4e0a\u7684PD-1\u819c\u53d7\u4f53\u7684\u65b0\u578bIgG4\u4eba\u6e90\u5316\u5355\u514b\u9686\u6297\u4f53\u3002\u5728\u8bd5\u9a8c\u5b89\u5168\u5ba1\u67e5\u59d4\u5458\u4f1a\uff08SRC\uff09\u53ec\u5f00\u4f1a\u8bae\u4e4b\u540e\uff0cSRC\u786e\u5b9a\u8fc4\u4eca\u4e3a\u6b62\u7684\u5b89\u5168\u6027\u6570\u636e\u8868\u660eCBT-501\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\uff0c\u5e76\u5efa\u8bae\u4e86\u5242\u91cf\u548c\u5f00\u53d1\u65f6\u95f4\u8ba1\u5212\u30021b\u671f\u5c06\u8bc4\u4f30\u56db\u79cd\u80bf\u7624\u7c7b\u578b\uff0c\u6bcf\u79cd\u7c7b\u578b\u9884\u8ba1\u62db\u52df\u7ea620\u540d\u60a3\u8005\u3002\u76ee\u524d\u5df2\u7ecf\u5f00\u5c55\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6b63\u5728\u6fb3\u5927\u5229\u4e9a\u8fdb\u884c\u3002<\/span><\/p>\n


<\/p>\n

5. Gossamer Bio\u516c\u53f8\u5b8c\u62102.3\u4ebf\u7f8e\u5143\u7684B\u8f6e\u878d\u8d44\uff0c\u4e13\u6ce8\u514d\u75ab\u7597\u6cd5<\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u65e5\u524d\uff0c\u4f4d\u4e8e\u7f8e\u56fd\u5723\u5730\u4e9a\u54e5\u7684Gossamer Bio\u516c\u53f8\u5ba3\u5e03\u5b8c\u6210\u6570\u989d\u4e3a2.3\u4ebf\u7f8e\u5143\u7684<\/span>B\u8f6e\u878d\u8d44<\/span><\/a>\u3002\u672c\u8f6e\u878d\u8d44\u7531\u9ad8\u74f4\u8d44\u672c\u96c6\u56e2\uff08Hillhouse Capital\uff09\u9886\u6295\uff0c\u83b7\u5f97\u7684\u8d44\u91d1\u5c06\u7528\u4e8e\u63a8\u8fdb\u591a\u4e2a\u524d\u671f\u548c\u540e\u671f\u5019\u9009\u836f\u7269\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u4ee5\u53ca\u63a8\u52a8\u516c\u53f8\u7684\u5feb\u901f\u53d1\u5c55\u3002Gossamer Bio\u516c\u53f8\u4e13\u6ce8\u4e8e\u5f00\u53d1\u57fa\u4e8e\u514d\u75ab\u5b66\u7684\u521b\u65b0\u7597\u6cd5\uff0c\u4e3b\u8981\u805a\u7126\u7684\u533b\u7597\u9886\u57df\u4e3a\u81ea\u8eab\u514d\u75ab\u75be\u75c5\uff0c\u8fc7\u654f\/\u708e\u75c7\uff0c\u80bf\u7624\u514d\u75ab\u5b66\u548c\u7ea4\u7ef4\u5316\u75be\u75c5\u3002\u8be5\u516c\u53f8\u5229\u7528\u81ea\u8eab\u5728\u514d\u75ab\u751f\u7269\u5b66\u673a\u5236\u7814\u7a76\u65b9\u9762\u7684\u4e13\u957f\uff0c\u901a\u8fc7\u6388\u6743\u5f15\u8fdb\uff08in-licensing\uff09\u514d\u75ab\u5b66\u9886\u57df\u524d\u666f\u770b\u597d\u7684\u5019\u9009\u836f\u7269\uff0c\u5bf9\u591a\u79cd\u836f\u7269\u8fdb\u884c\u5e73\u884c\u5f00\u53d1\u3002\u5229\u7528\u8fd9\u79cd\u72ec\u7279\u7b56\u7565\uff0cGossamer Bio\u516c\u53f8\u529b\u56fe\u8de8\u8d8a\u836f\u7269\u7814\u53d1\u521d\u671f\u7684\u74f6\u9888\uff0c\u52a0\u5feb\u53ef\u80fd\u663e\u8457\u6539\u5584\u60a3\u8005\u751f\u6d3b\u7684\u836f\u7269\u7684\u7814\u53d1\u901f\u5ea6\u3002<\/span><\/p>\n


<\/p>\n

6. BMS\u4e0e\u6e05\u534e\u5927\u5b66\u5408\u4f5c\u5f00\u53d1\u81ea\u8eab\u514d\u75ab\u75be\u75c5\u548c\u764c\u75c7\u836f\u7269 <\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\uff08BMS\uff09\u4e0e\u6e05\u534e\u5927\u5b66\u6b63\u5f0f<\/span>\u8fbe\u6210\u6218\u7565\u5408\u4f5c<\/span><\/a>\uff0c\u53cc\u65b9\u5c06\u5728\u81ea\u8eab\u514d\u75ab\u75be\u75c5\u548c\u764c\u75c7\u9886\u57df\u5f00\u5c55\u5408\u4f5c\uff0c\u5171\u540c\u53d1\u73b0\u548c\u7814\u7a76\u5177\u5907\u65b0\u9776\u70b9\u7684\u6cbb\u7597\u836f\u7269\u3002<\/span>\u636e\u4ecb\u7ecd\uff0cBMS\u548c\u6e05\u534e\u5927\u5b66\u5c06\u8054\u5408\u5404\u81ea\u7684\u79d1\u7814\u4f18\u52bf\u4e0e\u4e13\u4e1a\u80fd\u529b\uff0c\u4e13\u6ce8\u4e8e\u65b0\u9776\u70b9\u7684\u9a8c\u8bc1\uff0c\u5e76\u4fc3\u8fdb\u65e9\u671f\u5019\u9009\u836f\u7269\u7684\u53d1\u73b0\u53ca\u5176\u5411\u4e34\u5e8a\u7814\u53d1\u7684\u8f6c\u5316\u3002\u6839\u636e\u5408\u4f5c\u534f\u8bae\uff0c\u6e05\u534e\u5927\u5b66\u514d\u75ab\u6cbb\u7597\u521b\u65b0\u4e2d\u5fc3\uff08ICIT\uff09\u5c06\u8d1f\u8d23\u843d\u5b9e\u8fd9\u4e9b\u9879\u76ee\u7684\u7814\u7a76\uff0cBMS\u5219\u5c06\u62e5\u6709\u83b7\u53d6\u8be5\u4e2d\u5fc3\u5c31\u8fd9\u4e9b\u9879\u76ee\u6240\u7814\u53d1\u836f\u7269\u72ec\u5bb6\u6388\u6743\u7684\u4f18\u5148\u6743\u3002<\/span><\/p>\n


<\/p>\n

\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\u4e0e\u6e05\u534e\u5927\u5b66\u81ea2012\u5e74\u8d77\u5373\u5f00\u59cb\u5f00\u5c55\u79d1\u7814\u5408\u4f5c\uff0c\u91cd\u70b9\u4e13\u6ce8\u4e8e\u81ea\u8eab\u514d\u75ab\u9776\u70b9\u53d1\u73b0\u3001\u7ed3\u6784\u751f\u7269\u5b66\u7814\u7a76\u3001\u4ee5\u53ca\u89e3\u51b3\u751f\u7269\u5206\u5b50\u9776\u6807\u76843D\u86cb\u767d\u8d28\u7ed3\u6784\u7b49\u79d1\u7814\u9886\u57df\u3002\u4eca\u5e743\u6708\uff0cBMS\u8fd8\u4e0eICIT\u5c31\u514d\u75ab\u6cbb\u7597\u7814\u7a76\u548c\u521b\u65b0\u836f\u5f00\u53d1\u7b7e\u7f72\u4e86\u8c05\u89e3\u5907\u5fd8\u5f55\u3002\u672c\u6b21\u6240\u8fbe\u6210\u7684\u6218\u7565\u5408\u4f5c\uff0c\u6b63\u662f\u4e4b\u524d\u53cc\u65b9\u957f\u671f\u5408\u4f5c\u5173\u7cfb\u7684\u8fdb\u4e00\u6b65\u6269\u5927\u548c\u6df1\u5316\u3002<\/span><\/p>\n


<\/p>\n

\u53c2\u8003\u8d44\u6599\uff1a<\/span><\/p>\n

[1] \t<\/span>Gossamer Bio Announces $230 Million Series B Financing<\/span><\/p>\n

[2] \t<\/span>KEYTRUDA\u00ae (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS \u226520)<\/span><\/p>\n

[3] \t<\/span>CBT Pharmaceuticals Initiates Phase 1b Clinical Trial for Anti-PD-1 Antibody CBT-501-01 (genolimzumab injection) in Patients with Advanced Solid Tumors<\/span><\/p>\n


<\/p>\n

\"\u76d8\u70b9<\/p>\n

\n

\u59cb\u53d1\u4e8e\u5fae\u4fe1\u516c\u4f17\u53f7\uff1a \u836f\u660e\u5eb7\u5fb7 <\/p>\n<\/blockquote>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u258e\u836f\u660e\u5eb7\u5fb7\/\u62a5\u9053 \u56fe\u7247\u6765\u6e90\uff1a123RF 1. \u9ed8\u6c99\u4e1cPD-1\u5355\u6297Keytruda\u5728\u4e2d\u56fd\u83b7\u6279\u4e0a\u5e02 7\u670826\u65e5\uff0c\u9ed8 […]<\/p>\n","protected":false},"author":1,"featured_media":29507,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/29506"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=29506"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/29506\/revisions"}],"predecessor-version":[{"id":29513,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/29506\/revisions\/29513"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/29507"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=29506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=29506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=29506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}